Presented by Dr. Jamie Tyler, PhD: Noninvasive neuromodulation systems and devices are used everyday around the world for research, to treat medical indications, to enhance human performance, and in other consumer wellness and electronics applications [1, 2]. Our scientific, technical, and engineering efforts have led to the development and deployment of several distinct methods, which will be discussed. Transcranial focused ultrasound (tFUS) provides the highest spatial resolution of all the noninvasive neuromodulation methods [3, 4]. It also enables the focal, noninvasive neuromodulation of deep-brain circuits in humans [5]. Translational efforts have shown promise that tFUS can provide therapuetic benefits for several mental health conditions [6]. We will discuss recent evidence and emerging indications for the use of tFUS in modulating brain plasticity, sensory awareness, decision making, and mood [7-10]. Other bottom-up methods targeting brainstem nuclei of the reticular activating system will be discussed. These transdermal electrical nerve stimulation methods include trigeminal nerve stimulation and transdermal auricular vagus nerve stimulation (taVNS), which have been shown to modulate sympathetic tone and enhance brain plasticity by affecting the activity of the locus coeruleus and norepinephrine signalling [11-19]. We will describe collective efforts using trigeminal nerve stimulation and taVNS to provide active control of sympathetic nervous system activity for regulating alertness, attention, stress, anxiety, learning, and sleep/wake cycles. In all cases we will discuss the central role of quantitative psychophysiological and neurophysiological biomarkers in the iterative development, validation, and verification of these noninvasive neuromodulation methods. Emerging machine learning and artificial intelligence methods now promise to mine large data sets from similarly connected biosensors in real world environments. Therefore, we will discuss how these approaches are being integrated with noninvasive neuromodulation methods in open-loop and closed-loop manners to develop personalized approaches, advance our understanding of brain and behavior, and enable the optimization of human health and performance [1, 20, 21]. Finally we will discuss modern regulatory, ethical, and legal considerations for the investigation, use, and commercialization of noninvasive neurotechnologies intended to modulate or measure human brain activity in various applications.
2020: Neuromodulation Techniques for Altering Brain Plasticity and Cognition (Keynote)
Presented by Dr. Jamie Tyler, PhD: Noninvasive neuromodulation systems and devices are used everyday around the world for research, to treat medical indications, to enhance human performance, and in other consumer wellness and electronics applications [1, 2]. Our scientific, technical, and engineering efforts have led to the development and deployment of several distinct methods, which will be discussed. Transcranial focused ultrasound (tFUS) provides the highest spatial resolution of all the noninvasive neuromodulation methods [3, 4]. It also enables the focal, noninvasive neuromodulation of deep-brain circuits in humans [5]. Translational efforts have shown promise that tFUS can provide therapuetic benefits for several mental health conditions [6]. We will discuss recent evidence and emerging indications for the use of tFUS in modulating brain plasticity, sensory awareness, decision making, and mood [7-10]. Other bottom-up methods targeting brainstem nuclei of the reticular activating system will be discussed. These transdermal electrical nerve stimulation methods include trigeminal nerve stimulation and transdermal auricular vagus nerve stimulation (taVNS), which have been shown to modulate sympathetic tone and enhance brain plasticity by affecting the activity of the locus coeruleus and norepinephrine signalling [11-19]. We will describe collective efforts using trigeminal nerve stimulation and taVNS to provide active control of sympathetic nervous system activity for regulating alertness, attention, stress, anxiety, learning, and sleep/wake cycles. In all cases we will discuss the central role of quantitative psychophysiological and neurophysiological biomarkers in the iterative development, validation, and verification of these noninvasive neuromodulation methods. Emerging machine learning and artificial intelligence methods now promise to mine large data sets from similarly connected biosensors in real world environments. Therefore, we will discuss how these approaches are being integrated with noninvasive neuromodulation methods in open-loop and closed-loop manners to develop personalized approaches, advance our understanding of brain and behavior, and enable the optimization of human health and performance [1, 20, 21]. Finally we will discuss modern regulatory, ethical, and legal considerations for the investigation, use, and commercialization of noninvasive neurotechnologies intended to modulate or measure human brain activity in various applications.
$30.00
